Presenilin 2 is the predominant γ-Secretase in microglia and modulates cytokine release

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Jayadev, Suman ^a   Case, Amanda ^a   Eastman, Alison J ^a   Nguyen, Huy ^b   Pollak, Julia ^a   Wiley, Jesse C ^a   Möller, Thomas ^a   Morrison, Richard S ^c   Garden, Gwenn A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PRESENILIN 1; PRESENILIN 2; SHORT HAIRPIN RNA; TUMOR NECROSIS FACTOR ALPHA; AMYLOID PRECURSOR PROTEIN; SECRETASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; GENETIC TRANSCRIPTION; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; IN VITRO STUDY; INNATE IMMUNITY; MICROGLIA; MOUSE; NEGATIVE FEEDBACK; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PROTEIN FUNCTION; ANIMAL; CELL LINE; CENTRAL NERVOUS SYSTEM; GENE EXPRESSION REGULATION; GENETICS; METABOLISM;

MURINAE; MUS;

AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; CELL LINE; CENTRAL NERVOUS SYSTEM; CYTOKINES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; IMMUNITY, INNATE; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MICE; MICROGLIA; PRESENILIN-1; PRESENILIN-2; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78650807057     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015743     Document Type: Article

References (70)

1. Hass MR, Sato C, Kopan R, Zhao G (2009) Presenilin: RIP and beyond. Semin Cell Dev Biol 20: 201-210.
2. Wiley JC, Hudson M, Kanning KC, Schecterson LC, Bothwell M (2005) Familial Alzheimer's disease mutations inhibit gamma-secretase-mediated liberation of beta-amyloid precursor protein carboxy-terminal fragment. J Neurochem 94: 1189-1201.
3. Walker ES, Martinez M, Brunkan AL, Goate A (2005) Presenilin 2 familial Alzheimer's disease mutations result in partial loss of function and dramatic changes in Abeta 42/40 ratios. J Neurochem 92: 294-301.
4. Shen J, Kelleher RJ, 3rd (2007) The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism. Proc Natl Acad Sci U S A 104: 403-409.
5. Heilig EA, Xia W, Shen J, Kelleher RJ (2010) A presenilin-1 mutation identified in familial Alzheimer's disease with cotton wool plaques causes nearly complete loss of {gamma}-secretase activity. J Biol Chem.
6. Tysoe C, Whittaker J, Xuereb J, Cairns NJ, Cruts M, et al. (1998) A presenilin-1 truncating mutation is present in two cases with autopsy-confirmed early-onset Alzheimer disease. Am J Hum Genet 62: 70-76.
7. Jayadev S, Leverenz JB, Steinbart E, Stahl J, Klunk W, et al. (2010) Alzheimer's disease phenotypes and genotypes associated with mutations in presenilin 2. Brain 133: 1143-1154.
8. Saura CA, Choi SY, Beglopoulos V, Malkani S, Zhang D, et al. (2004) Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron 42: 23-36.
9. Beglopoulos V, Sun X, Saura CA, Lemere CA, Kim RD, et al. (2004) Reduced beta-amyloid production and increased inflammatory responses in presenilin conditional knock-out mice. J Biol Chem 279: 46907-46914.
10. Feng R,Wang H, Wang J, Shrom D, Zeng X, et al. (2004) Forebrain degeneration and ventricle enlargement caused by double knockout of Alzheimer's presenilin-1 and presenilin-2. Proc Natl Acad Sci U S A 101: 8162-8167.
11. Saban MR, Nguyen NB, Hammond TG, Saban R (2002) Gene expression profiling of mouse bladder inflammatory responses to LPS, substance P, and antigen-stimulation. Am J Pathol 160: 2095-2110.
12. Yagi T, Giallourakis C, Mohanty S, Scheidig C, Shen J, et al. (2008) Defective signal transduction in B lymphocytes lacking presenilin proteins. Proc Natl Acad Sci U S A 105: 979-984.
13. Lee J, Chan SL, Mattson MP (2002) Adverse effect of a presenilin-1 mutation in microglia results in enhanced nitric oxide and inflammatory cytokine responses to immune challenge in the brain. Neuromolecular Med 2: 29-45.
14. Wyss-Coray T (2006) Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med 12: 1005-1015.
15. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, et al. (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21: 383-421.
16. Lehnardt S (2010) Innate immunity and neuroinflammation in the CNS: the role of microglia in Toll-like receptor-mediated neuronal injury. Glia 58: 253-263.
17. Lee JK, Tran T, Tansey MG (2009) Neuroinflammation in Parkinson's disease. J Neuroimmune Pharmacol 4: 419-429.
18. Mrak RE (2009) Neuropathology and the neuroinflammation idea. J Alzheimers Dis 18: 473-481.
19. Bamberger ME, Landreth GE (2002) Inflammation, apoptosis, and Alzheimer's disease. Neuroscientist 8: 276-283.
20. Hanisch UK, Kettenmann H (2007) Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 10: 1387-1394.
21. Ransohoff RM, Perry VH (2009) Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol 27: 119-145.
22. Colton CA (2009) Heterogeneity of microglial activation in the innate immune response in the brain. J Neuroimmune Pharmacol 4: 399-418.
23. Town T, Nikolic V, Tan J (2005) The microglial ''activation'' continuum: from innate to adaptive responses. J Neuroinflammation 2: 24.
24. Walter S, Letiembre M, Liu Y, Heine H, Penke B, et al. (2007) Role of the tolllike receptor 4 in neuroinflammation in Alzheimer's disease. Cell Physiol Biochem 20: 947-956.
25. Okun E, Griffioen KJ, Lathia JD, Tang SC, Mattson MP, et al. (2009) Toll-like receptors in neurodegeneration. Brain Res Rev 59: 278-292.
26. Akira S, Takeda K (2004) Toll-like receptor signalling. Nat Rev Immunol 4: 499-511.
27. Holmes C, Cunningham C, Zotova E, Woolford J, Dean C, et al. (2009) Systemic inflammation and disease progression in Alzheimer disease. Neurology 73: 768-774.
28. Tarkowski E, Andreasen N, Tarkowski A, Blennow K (2003) Intrathecal inflammation precedes development of Alzheimer's disease. J Neurol Neurosurg Psychiatry 74: 1200-1205.
29. Floden AM, Li S, Combs CK (2005) Beta-amyloid-stimulated microglia induce neuron death via synergistic stimulation of tumor necrosis factor alpha and NMDA receptors. J Neurosci 25: 2566-2575.
30. Coraci IS, Husemann J, Berman JW, Hulette C, Dufour JH, et al. (2002) CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer's disease brains and can mediate production of reactive oxygen species in response to beta-amyloid fibrils. Am J Pathol 160: 101-112.
31. Barry SC, Harder B, Brzezinski M, Flint LY, Seppen J, et al. (2001) Lentivirus vectors encoding both central polypurine tract and posttranscriptional regulatory element provide enhanced transduction and transgene expression. Hum Gene Ther 12: 1103-1108.
32. Balcaitis S, Weinstein JR, Li S, Chamberlain JS, Moller T (2005) Lentiviral transduction of microglial cells. Glia 50: 48-55.
33. Maccioni RB, Rojo LE, Fernandez JA, Kuljis RO (2009) The role of neuroimmunomodulation in Alzheimer's disease. Ann N Y Acad Sci 1153: 240-246.
34. De Strooper B (2003) Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. Neuron 38: 9-12.
35. Lai MT, Chen E, Crouthamel MC, Di Muzio-Mower J, Xu M, et al. (2003) Presenilin-1 and presenilin-2 exhibit distinct yet overlapping gamma-secretase activities. J Biol Chem 278: 22475-22481.
36. Mastrangelo P, Mathews PM, Chishti MA, Schmidt SD, Gu Y, et al. (2005) Dissociated phenotypes in presenilin transgenic mice define functionally distinct gamma-secretases. Proc Natl Acad Sci U S A 102: 8972-8977.
37. Thinakaran G, Harris CL, Ratovitski T, Davenport F, Slunt HH, et al. (1997) Evidence that levels of presenilins (PS1 and PS2) are coordinately regulated by competition for limiting cellular factors. J Biol Chem 272: 28415-28422.
38. Gordon S (2003) Alternative activation of macrophages. Nat Rev Immunol 3: 23-35.
39. Gifford GE, Lohmann-Matthes ML (1987) Gamma interferon priming of mouse and human macrophages for induction of tumor necrosis factor production by bacterial lipopolysaccharide. J Natl Cancer Inst 78: 121-124.
40. Blasko I, Ransmayr G, Veerhuis R, EikelenboomP,Grubeck-Loebenstein B (2001) Does IFNgamma play a role in neurodegeneration? J Neuroimmunol 116: 1-4.
41. Huberman M, Shalit F, Roth-Deri I, Gutman B, Brodie C, et al. (1994) Correlation of cytokine secretion by mononuclear cells of Alzheimer patients and their disease stage. J Neuroimmunol 52: 147-152.
42. Mastrangelo MA, Sudol KL, Narrow WC, Bowers WJ (2009) Interferon-{gamma} differentially affects Alzheimer's disease pathologies and induces neurogenesis in triple transgenic-AD mice. Am J Pathol 175: 2076-2088.
43. Yamamoto M, Kiyota T, Horiba M, Buescher JL, Walsh SM, et al. (2007) Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. Am J Pathol 170: 680-692.
44. Lees JR, Golumbek PT, Sim J, Dorsey D, Russell JH (2008) Regional CNS responses to IFN-gamma determine lesion localization patterns during EAE pathogenesis. J Exp Med 205: 2633-2642.
45. Chakrabarty P, Ceballos-Diaz C, Beccard A, Janus C, Dickson D, et al. (2010) IFN-{gamma} Promotes Complement Expression and Attenuates Amyloid Plaque Deposition in Amyloid {beta} Precursor Protein Transgenic Mice. J Immunol.
46. Schulte A, Schulz B, Andrzejewski MG, Hundhausen C, Mletzko S, et al. (2007) Sequential processing of the transmembrane chemokines CX3CL1 and CXCL16 by alpha-and gamma-secretases. Biochem Biophys Res Commun 358: 233-240.
47. Zurhove K, Nakajima C, Herz J, Bock HH, May P (2008) Gamma-secretase limits the inflammatory response through the processing of LRP1. Sci Signal 1: ra15.
48. Pocivavsek A, Mikhailenko I, Strickland DK, Rebeck GW (2009) Microglial lowdensity lipoprotein receptor-related protein 1 modulates c-Jun N-terminal kinase activation. J Neuroimmunol 214: 25-32.
49. Elzinga BM, Twomey C, Powell JC, Harte F, McCarthy JV (2009) Interleukin-1 receptor type 1 is a substrate for gamma-secretase-dependent regulated intramembrane proteolysis. J Biol Chem 284: 1394-1409.
50. Kuhn PH, Marjaux E, Imhof A, De Strooper B, Haass C, et al. (2007) Regulated intramembrane proteolysis of the interleukin-1 receptor II by alpha-, beta-, and gamma-secretase. J Biol Chem 282: 11982-11995.
51. Carey BW, Kim DY, Kovacs DM (2007) Presenilin/gamma-secretase and alpha-secretase-like peptidases cleave human MHC Class I proteins. Biochem J 401: 121-127.
52. Kopan R, Ilagan MX (2009) The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 137: 216-233.
53. Palaga T, Buranaruk C, Rengpipat S, Fauq AH, Golde TE, et al. (2008) Notch signaling is activated by TLR stimulation and regulates macrophage functions. Eur J Immunol 38: 174-183.
54. Monsalve E, Perez MA, Rubio A, Ruiz-Hidalgo MJ, Baladron V, et al. (2006) Notch-1 up-regulation and signaling following macrophage activation modulates gene expression patterns known to affect antigen-presenting capacity and cytotoxic activity. J Immunol 176: 5362-5373.
55. Hu X, Chung AY, Wu I, Foldi J, Chen J, et al. (2008) Integrated regulation of Toll-like receptor responses by Notch and interferon-gamma pathways. Immunity 29: 691-703.
56. Grandbarbe L, Michelucci A, Heurtaux T, Hemmer K, Morga E, et al. (2007) Notch signaling modulates the activation of microglial cells. Glia 55: 1519-1530.
57. Ong CT, Sedy JR, Murphy KM, Kopan R (2008) Notch and presenilin regulate cellular expansion and cytokine secretion but cannot instruct Th1/Th2 fate acquisition. PLoS One 3: e2823.
58. Terai K, Matsuo A, McGeer EG, McGeer PL (1996) Enhancement of immunoreactivity for NF-kappa B in human cerebral infarctions. Brain Res 739: 343-349.
59. Pennypacker KR, Fuldner R, Xu R, Hernandez H, Dawbarn D, et al. (1998) Cloning and characterization of the presenilin-2 gene promoter. Brain Res Mol Brain Res 56: 57-65.
60. Semenza GL (1998) Hypoxia-inducible factor 1: master regulator of O2 homeostasis. Curr Opin Genet Dev 8: 588-594.
61. Satoh J, Kuroda Y (1999) Constitutive and cytokine-regulated expression of presenilin-1 and presenilin-2 genes in human neural cell lines. Neuropathol Appl Neurobiol 25: 492-503.
62. Lee MK, Slunt HH, Martin LJ, Thinakaran G, Kim G, et al. (1996) Expression of presenilin 1 and 2 (PS1 and PS2) in human and murine tissues. J Neurosci 16: 7513-7525.
63. Choi SH, Veeraraghavalu K, Lazarov O, Marler S, Ransohoff RM, et al. (2008) Non-cell-autonomous effects of presenilin 1 variants on enrichment-mediated hippocampal progenitor cell proliferation and differentiation. Neuron 59: 568-580.
64. Kang DE, Yoon IS, Repetto E, Busse T, Yermian N, et al. (2005) Presenilins mediate phosphatidylinositol 3-kinase/AKT and ERK activation via select signaling receptors. Selectivity of PS2 in platelet-derived growth factor signaling. J Biol Chem 280: 31537-31547.
65. Placanica L, Tarassishin L, Yang G, Peethumnongsin E, Kim SH, et al. (2009) Pen2 and presenilin-1 modulate the dynamic equilibrium of presenilin-1 and presenilin-2 gamma-secretase complexes. J Biol Chem 284: 2967-2977.
66. Wolozin B, Iwasaki K, Vito P, Ganjei JK, Lacana E, et al. (1996) Participation of presenilin 2 in apoptosis: enhanced basal activity conferred by an Alzheimer mutation. Science 274: 1710-1713.
67. 2+ signaling. FASEB J 19: 2069-2071.
68. 2+ disruption in Alzheimer's disease by presenilin regulation of InsP3 receptor channel gating. Neuron 58: 871-883.
69. Lee SY, Hwang DY, Kim YK, Lee JW, Shin IC, et al. (2006) PS2 mutation increases neuronal cell vulnerability to neurotoxicants through activation of caspase-3 by enhancing of ryanodine receptor-mediated calcium release. FASEB J 20: 151-153.
70. 2+ leak channels, a function disrupted by familial Alzheimer's disease-linked mutations. Cell 126: 981-993.